Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation.
Percutaneous transluminal coronary angioplasty is a routinely used non-surgical revascularization technique for patients with coronary artery disease. Up to 30% of patients undergoing coronary angioplasty develop a renarrowing of treated vessels, called restenosis. Smooth muscle cell proliferation is thought to be an important factor in restenosis; this leads to neointima formation and arterial lumen narrowing. Neointima may be reduced by the transfer of genes encoding proteins with antiproliferative effects. Cecropins are antimicrobial peptides with antiproliferative properties in mammalian cells. Cecropin A is one member of this family of peptides. In this article, a plasmid carrying the gene for the immature form, pre-pro-cecropin A, complexed with liposomes was locally delivered to perivascular tissue in a porcine arterial injury model using a needle injection catheter. Retention of the plasmid in the treated arteries was demonstrated at both 8 and 21 days following application. Transferred plasmid DNA was not detected in any other tissues analyzed. Pre-pro-cecropin A-specific transcripts could also be found in treated arteries. Balloon-injured vessels demonstrated significantly reduced neointima at 21 days in vessels treated with the pre-pro-cecropin A gene compared with neointimal area in those given a control gene (P < 0.05). The needle injection catheter appears to be useful for local intravascular gene delivery. In vivo gene transfer of cecropins may be of therapeutic relevance in restenosis prevention by limiting cell proliferation.
Nikol
S
S
Medical Department I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Huehns
T Y
TY
Krausz
E
E
Armeanu
S
S
Engelmann
M G
MG
Winder
D
D
Salmons
B
B
Hoefling
B
B
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism*; D023181:Antimicrobial Cationic Peptides; D002455:Cell Division / Q000235:genetics; D003327:Coronary Disease / Q000628:therapy*; D015316:Genetic Therapy / Q000295:instrumentation / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D007150:Immunohistochemistry; D007267:Injections; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D010455:Peptides / Q000235:genetics*; D011355:Prodrugs / Q000378:metabolism; D012008:Recurrence; D013552:Swine
D000890:Anti-Infective Agents; D023181:Antimicrobial Cationic Peptides; D010455:Peptides; D011355:Prodrugs; C031161:cecropin A